Additionally, WES of multiple tissue and plasma biopsies from a bile duct cancer patient (Pt5) illustrated a dominant tumor clone characterized by a pathogenic TP53 mutation and the treatment target BRAF V600E detected in all solid and liquid biopsies, possibly explaining the good response observed for this patient. Here, TP53 is linked to neoplasm.